4.6 Article

The PRECIS-2 tool has good interrater reliability and modest discriminant validity

期刊

JOURNAL OF CLINICAL EPIDEMIOLOGY
卷 88, 期 -, 页码 113-121

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jclinepi.2017.06.001

关键词

Randomized controlled trials; Clinical trial methodology; Validity and reliability; Face validity; Pragmatic clinical trial; Trial design

资金

  1. Chief Scientist Office (CSO) of Scotland [CZH/4/773]
  2. UK Medical Research Council
  3. University of Dundee
  4. Health Services Research Unit at the University of Aberdeen
  5. CSO of the Scottish Government Health Directories
  6. Chief Scientist Office [CZH/4/773, NMAHP2] Funding Source: researchfish

向作者/读者索取更多资源

Objectives: PRagmatic Explanatory Continuum Indicator Summary (PRECIS)-2 is a tool that could improve design insight for trialists. Our aim was to validate the PRECIS-2 tool, unlike its predecessor, testing the discriminant validity and interrater reliability. Study Design and Setting: Over 80 international trialists, methodologists, clinicians, and policymakers created PRECIS-2 helping to ensure face validity and content validity. The interrater reliability of PRECIS-2 was measured using 19 experienced trialists who used PRECIS-2 to score a diverse sample of 15 randomized controlled trial protocols. Discriminant validity was tested with two raters to independently determine if the trial protocols were more pragmatic or more explanatory, with scores from the 19 raters for the 15 trials as predictors of pragmatism. Results: Interrater reliability was generally good, with seven of nine domains having an intraclass correlation coefficient over 0.65. Flexibility (adherence) and recruitment had wide confidence intervals, but raters found these difficult to rate and wanted more information. Each of the nine PRECIS-2 domains could be used to differentiate between trials taking more pragmatic or more explanatory approaches with better than chance discrimination for all domains. Conclusion: We have assessed the validity and reliability of PRECIS-2. An elaboration study and web site provide guidance to help future users of the tool which is continuing to be tested by trial teams, systematic reviewers, and funders. (C) 2017 Elsevier Inc. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据